GLP-1 compounding is moving from shortage-era access to enforcement-era scrutiny.
The tracker prioritizes FDA shortage notices, 503A and 503B policy, warning letters, and OIG oversight signals.
Peptide Tracker
Unvarnished peptide updates, ready for editorial review.
A source-first queue for FDA actions, GLP-1 compounding policy, warning letters, anti-doping rules, pharmacy oversight, and trade-body responses. These are not rewritten press releases; every item starts with the source that should anchor the article.
20active source items
5primary-source channels
6ready to paraphrase
1424-hour news candidates
Injectable quality and dosing-error notices belong on safety pages, not buried in footnotes.
When FDA flags dosing errors, sterility, or CGMP concerns, the relevant profile and access pages should get revised.
Peptide-hormone claims need WADA context before any performance framing.
WADA is treated as the source of record for anti-doping status, with clinical evidence handled separately.
Latest brief
Read brief Baptist Health Experts Warn of Safety and Legal Risks in Unregulated Peptide Market
Online marketplaces and social media platforms are aggressively promoting peptides for wellness, weight loss, and anti-aging, but experts at Baptist Health warn that the digital marketpla
Latest Peptide News
Latest 24 Hours of Peptide News
Medriva tracks current peptide, GLP-1, regulatory, clinical, and industry coverage, then keeps the most relevant developments here for brief selection and editorial follow-up.
FDA peptides , MAHA alcohol, Medicaid lawsuit: Morning Rounds
Medriva is tracking this as a current peptide-news lead for review against the original publisher page.
Content angle: Check whether this changes peptide safety, access, compounding, or regulatory guidance.
Cross-agency targeted campaign “Peptides 2026”
Cross-agency targeted campaign “Peptides 2026” Skip to main content Swiss federal authorities Subscribe to news Language dropdown English selected DE FR IT EN RM The Federal Council The portal of the Swiss government The portal of the Swiss government The Federal Council The portal of the Swiss government Search Search Media Services Contact Subscribe
Content angle: Review as a possible same-day peptide news brief lead or tracker update.
Should San Antonio stop paying for things that charge a ticket fee?
San Antonio is staring down a $158 million budget hole — and Mayor Gina Ortiz Jones is drawing a hard line: if you charge a ticket fee, the city shouldn't be footing the bill. That means the San Antonio Botanical Garden could go from $1.2 million in city funding to zero. Garrett Brnger dug into what cuts could actually mean for organizations that depend
Content angle: Review as a possible same-day peptide news brief lead or tracker update.
FDA staff recommendation undercuts RFK Jr.'s push to expand peptides
Medriva is tracking this as a current peptide-news lead for review against the original publisher page.
Content angle: Check whether this changes peptide safety, access, compounding, or regulatory guidance.
- YouTube
Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.
Content angle: Review as a possible same-day peptide news brief lead or tracker update.
Unlock Muscle Growth: The Retta Peptide Advantage Explained #shorts
Medriva is tracking this as a current peptide-news lead for review against the original publisher page.
Content angle: Review as a possible same-day peptide news brief lead or tracker update.
HLB Peptide Signs Main CDMO Contract with Japan
On June 30, HLB Peptide announced that it has signed a main contract for contract development and manufacturing organization (CDMO) services with Pept
Content angle: Review as a possible same-day peptide news brief lead or tracker update.
The Peptide Boom: Why This Ingredient Is Taking Over
If you've heard peptides mentioned alongside scalp health, there's good reason. A trichologist explains what peptide-based haircare can do.
Content angle: Review as a possible same-day peptide news brief lead or tracker update.
Peptide therapies — popular, unproven, dangerous
Americans have become accustomed to taking peptides for for improved health, but unless they've undergone clinical trials and received FDA approval, there's no way to establish a peptide's safety or effectiveness.
Content angle: Check whether this changes peptide safety, access, compounding, or regulatory guidance.
Biweekly glucagon-like peptide-1 receptor agonist bofanglutide improves glycemic control
1. In this randomized controlled trial, biweekly injections of the novel glucagon-like peptide-1 receptor agonist (GLP-1RA) bofanglutide resulted in greater reductions in hemoglobin A1c (HbA1c) compared with semaglutide in patients with type 2 diabetes mellitus (T2DM). 2. Both treatments were associated with improvements in fasting plasma glucose, body weigh
Content angle: Check whether this changes peptide safety, access, compounding, or regulatory guidance.
FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
When U.S. health officials meet next month to reconsider a list of controversial peptide drugs, they will hear from a new set of voices: doctors and pharmacists with deep financial ties to the burgeoning industry of unproven chemicals.
Content angle: Check whether this changes peptide safety, access, compounding, or regulatory guidance.
Peptide Tracker Rolls Out Major Update: Honest Adherence Tracking, Smart Injection-Site Rotation, and In-App Vial Reconstitution
Peptide Tracker, the free protocol-tracking app for people managing peptide regimens, today released a major update that turns the app into an end-to-end companion for building, dosing, and tracking peptide protocols. The release rounds out the app
Content angle: Use as market context only, separating access and business signals from clinical evidence.
Peptides for Wellness, Weight Loss, and Anti-Aging: What You Need to Know About Safety and Legality
Online marketplaces and social media platforms are heavily promoting a broad category of wellness products known as peptides. However, experts warn that the digital marketplace masks a complex landscape of varying product quality, shifting legal frameworks, and distinct safety profiles.
Content angle: Check whether this changes peptide safety, access, compounding, or regulatory guidance.
Peptides are the latest US health craze. But what exactly are they?
While peptides are taking the health and wellness category by storm for various use cases, what exactly are they? Leerink Partners senior research analyst Michael Cherny helps break down what a peptides are, how people are choosing them for personal health and recovery reasons, and who the biggest winners in consumer pharmaceuticals could be if their popular
Content angle: Evaluate whether the evidence changes a clinical, research, or mechanism-focused Medriva page.
Brief Archive
Search Medriva peptide briefs by date or topic
Source-led briefs and editorial dispatches are collected here after publication. Search by month, date, drug, regulator, or source theme, then open the archived item directly.
18 briefsLatest Tuesday, June 30th, 2026
Tuesday, June 30th, 2026Baptist Health Experts Warn of Safety and Legal Risks in Unregulated Peptide MarketOnline marketplaces and social media platforms are aggressively promoting peptides for wellness, weight loss, and anti-aging, but experts at Baptist Health warn that the digital marketplaMonday, June 29th, 2026New Peptide Shows Promise Against Antimicrobial-Resistant Infections, Study FindsResearchers have identified a novel peptide capable of treating antimicrobial-resistant infections, according to a study reported by NewsNation.Sunday, June 28th, 2026Peptide RX Token Appears on Coinbase Germany, Highlighting Crypto-Peptide Name ConfusionA cryptocurrency token branded "Peptide RX" (ticker PEPTIDE) has appeared on Coinbase Germany's price-tracking platform, trading at approximately €0.000009803 per token as of Sunday.Saturday, June 27th, 2026Double-Strength Retatrutide Peptide Prompts Overdose Warning From Australian DoctorsAustralian physicians are warning of "life-threatening" overdose risks after laboratory testing of an unapproved weight-loss peptide product found it contained twice the active ingredientFriday, June 26th, 2026Doctors Warn of Risks From Unregulated Peptides Marketed for Weight LossPhysicians are raising alarms about the growing popularity of unregulated peptide products sold for weight loss, warning consumers that these compounds carry unknown safety risks and areThursday, June 25th, 2026Biocon Advances Peptide Pipeline With Regulatory Approvals for GLP-1 AnalogsBiocon Ltd. has secured regulatory approvals for multiple peptide molecules and is prioritizing GLP-1 analog development, according to Dr.Wednesday, June 24th, 2026Huaxuan Launches Halal-Certified Bovine Collagen Peptides for Functional BeveragesChinese ingredient manufacturer Huaxuan announced the launch of Halal-certified bovine collagen peptides intended for use in functional beverages, according to a company press release disTuesday, June 23rd, 2026Ascletis Gains FDA Clearance for Once-Monthly Obesity PeptideAscletis Pharma announced it has received U.S. Food and Drug Administration clearance of its Investigational New Drug application to begin a Phase I study of ASC35, a once-monthly injectaMonday, June 22nd, 2026FDA Signals Broader Regulatory Scrutiny of Peptide ProductsThe U.S. Food and Drug Administration is intensifying its oversight of peptide products beyond the well-publicized GLP-1 drug class, according to a regulatory analysis published Monday bySunday, June 21st, 2026CKYN Launches Three-Step Copper Peptide Skincare SystemCKYN LLC announced the launch of The Complete CKYN Protocol, a three-step copper peptide skincare system manufactured in the United States, according to a company news release issued SatuSaturday, June 20th, 2026Waters Launches Columns Designed for Faster GLP-1 Peptide AnalysisWaters Corporation has introduced new reversed-phase liquid chromatography columns specifically engineered to accelerate analysis of GLP-1 peptide drugs and lipid nanoparticles, the compaFriday, June 19th, 2026Scientists Warn Popular 'Mother of All Antioxidants' Supplement Can Cause HarmA widely marketed dietary supplement often called the "mother of all antioxidants" may pose health risks, scientists are warning, according to a report published by Inc.Thursday, June 18th, 2026Gelteq Advances Peptide Pipeline With Veterinary and Human Clinical TrialsGelteq, a biotechnology company developing peptide-based therapeutics, announced it is launching both veterinary and human clinical trials as part of an expanded pharmaceutical pipeline sWednesday, June 17th, 2026Peptide Market Reaches $140B as Quality Divide Widens Between Regulated Drugs and Research-Only SupplyThe global peptide market has reached $140 billion, according to a new industry report released by Koi Peptides, which highlights a growing quality gap between FDA-approved therapeutic pe2026-06-05June 2026 Peptide News ArchiveJune opened with peptide policy, GLP-1 compounding, Retatrutide pipeline questions, and safety context moving together.2026-06-05May 2026 Peptide News Archive: Evidence Guide (2026)May brought GLP-1 access, compounding policy, telehealth marketing, warning-letter activity, and next-generation metabolic peptides into the same frame.2026-06-05TB-500 Is Just Thymosin β-4 Guide (2026)2026-06-05The Truth About GLP-1 and Alcohol: Guide (2026)
Source Queue
Monitored source queue
Each card links to the originating source and labels the regulatory, safety, clinical, or industry context that may need a future Medriva update.
2026-06-30FDA GLP-1 compounding updates
RegulatorSource reviewed
CDER Update
The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30FDA warning letters
RegulatorSource reviewed
Warning Letters
Main FDA Warning Letter Page
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30FDA human drug compounding
RegulatorSource reviewed
Compounding: Inspections, Recalls, and other Actions
Inspections, recalls and other actions of compounders under section 503A and outsourcing facilities under section 503B
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30WADA prohibited list
Sports regulatorSource reviewed
WADA prohibited list
Peptide hormones, growth factors, mimetics, and athlete-facing restrictions.
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30Alliance for Pharmacy Compounding
Trade bodySource reviewed
APC News Feed
News and more from the Alliance for Pharmacy Compounding
Why it matters: This industry context can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30Outsourcing Facilities Association
Trade bodySource reviewed
Outsourcing Facility Association - Drug Shortages - United States
Information relating to FDA recognized Drug Shortages and the Outsourcing Facility Association or OFA
Why it matters: This industry context can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30NABP
Pharmacy oversightSource reviewed
Newsroom
Get caught up with the latest in NABP pharmacy news. Access official news releases, program updates, reports, as well as blog posts from industry experts.
Why it matters: This verification layer can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30FDA press announcements
RegulatorSource reviewed
Press Announcements
Press Announcements
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30FDA drug safety communications
RegulatorSource reviewed
Drug Safety Communications
FDA Drug Safety Communications connect consumers and health care professionals to important drug safety information.
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30FDA drug shortages database
RegulatorSource reviewed
FDA Drug Shortages
FDA Drug Shortages Skip to main content Skip to FDA Search Skip to footer links An official website of the United States government Here's how you know The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensur
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30ClinicalTrials.gov incretin and peptide trials
Clinical trialsSource reviewed
ClinicalTrials.gov
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-30PubMed peptide and incretin literature
Medical literatureSource reviewed
peptide OR semaglutide OR tirzepatide OR cagrisema OR survodutide - Search Results - PubMed
peptide OR semaglutide OR tirzepatide OR cagrisema OR survodutide - Search Results - PubMed
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-04-30FDA
Proposed ruleReady to paraphrase
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List.
The proposal would keep 503B outsourcing facilities from compounding these GLP-1 active ingredients from bulk drug substances unless another legal pathway applies.
Why it matters: This is one of the clearest policy signals on where FDA wants the post-shortage GLP-1 compounding market to land.
Article angle: Explain what 503B facilities can and cannot do after the shortage-era enforcement discretion ends.
2026-04-15HHS OIG
Oversight work planWatch
Federal watchdog adds FDA oversight of compounded GLP-1 drugs to its work plan.
OIG flagged a review of FDA oversight for compounded GLP-1 drugs, with a final report expected later in the decade.
Why it matters: A watchdog review raises the odds of sharper documentation, inspection, and enforcement expectations around compounded GLP-1s.
Article angle: Track what OIG is asking, what FDA already controls, and what consumers should watch while the review is open.
2026-04-07FDA
Warning letterReady to paraphrase
FDA warning letter to ProRx cites outsourcing-facility quality and sterility concerns.
FDA identified CGMP and sterility-related concerns at a 503B outsourcing facility and tied the review to compounded drug products including GLP-1 preparations.
Why it matters: Quality-system failures are not abstract when a compounded injectable is involved; this belongs in every access and safety update.
Article angle: Turn the warning letter into a plain-English quality checklist for readers evaluating compounded injectables.
2026-03-03FDA
Enforcement noticeReady to paraphrase
FDA warns 30 telehealth companies over marketing of compounded GLP-1 drugs.
FDA said companies were making illegal marketing claims around compounded GLP-1 products and failing to communicate required risk context.
Why it matters: This separates evidence-led GLP-1 education from commercial copy that implies compounded products are FDA-approved substitutes.
Article angle: Create a reader guide on marketing claims that should trigger skepticism before buying or booking a consult.
2026-02-06FDA
Policy clarificationReady to paraphrase
FDA clarifies compounder policies as the national GLP-1 supply stabilizes.
FDA outlined enforcement-discretion end dates after resolving tirzepatide and semaglutide shortage status, with different windows for 503A and 503B compounders.
Why it matters: Many access and cost pages still repeat shortage-era assumptions. This is the source that resets that timeline.
Article angle: Publish a timeline showing when shortage-based compounding discretion ended and what exceptions remain.
2025-07-31FDA
Safety updateReady to paraphrase
FDA updates concerns about unapproved GLP-1 drugs used for weight loss.
FDA highlights dosing errors, adverse-event reports, and risks from unapproved GLP-1 products, including non-commercial active ingredients promoted online.
Why it matters: This is the safety anchor for pages on compounded semaglutide, tirzepatide, retatrutide claims, and copycat GLP-1 marketing.
Article angle: Build a safety explainer that distinguishes FDA-approved GLP-1 drugs from unapproved and copycat products.
2025-09-25WADA
Prohibited listReady to paraphrase
WADA publishes the 2026 Prohibited List covering peptide hormones and growth factors.
The prohibited list is the athlete-facing source for peptide hormones, growth factors, related substances, and mimetics.
Why it matters: Sports and recovery pages need a clear line between medical-use discussion and substances that can create anti-doping exposure.
Article angle: Translate the WADA peptide-hormone categories into a practical athlete safety page without giving evasion advice.
2026-02-06Alliance for Pharmacy Compounding
Trade-body responseContext only
Compounding trade body responds to FDA's GLP-1 API restriction plan.
The trade-body response is useful context for industry arguments, but it should be treated separately from FDA policy.
Why it matters: Readers deserve to see both the regulator's position and the industry's response without confusing them as equally authoritative.
Article angle: Create a source-comparison piece: what FDA says, what compounders say, and where patients still need clinician guidance.
